Entelo Bio Emerges from Stealth with $4M to Advance AI-Driven Movement Disorder Therapeutics
核心洞察
Entelo Bio (搜索), an AIxBio company focused on movement and aging biology, secured $4 million in funding led by Ananda Impact Ventures (搜索) to address conditions affecting 1.7 billion people worldwide.
The Oxford University spinout has developed proprietary clinical, wet-lab and AI infrastructure to fuel biological discovery and translation for movement-impairing conditions ranging from chronic age-associated diseases (搜索) to rare genetic disorders (搜索).
The company aims to transform human physical resilience through precision medicine approaches, leveraging multi-omics research from the Botnar Institute for Musculoskeletal Sciences (搜索) to develop and de-risk new therapeutics.
Entelo Bio (搜索), an artificial intelligence-driven biotechnology company focused on movement disorders (搜索) and aging, emerged from stealth mode with $4 million in funding to address the therapeutic needs of 1.7 billion people worldwide living with conditions that impair movement. The funding round was led by Ananda Impact Ventures (搜索), with participation from The Creator Fund (搜索) and bio- and tech-focused angel investors from the US and Europe.
Addressing a Global Health Challenge
The Oxford University spinout has developed what it describes as a proprietary clinical, wet-lab and AI infrastructure designed to fuel biological discovery and translation for movement-impairing conditions. These conditions span from chronic age-associated diseases (搜索) to rare genetic disorders (搜索), representing a significant unmet medical need in an aging global population.
"Transforming human physical resilience is the most pressing challenge facing a rapidly ageing society," said Prof Adam Cribbs, Co-Founder and CTO of Entelo Bio (搜索). "At Entelo Bio, we've built the frontier system for human physical resilience. We generate the right human data from our global clinical community to fuel our AI, and the human-centric disease models to validate what it predicts."
AI-Powered Drug Discovery Platform
The company's approach centers on leveraging artificial intelligence to improve the quality of biological data used in drug discovery. According to Dr Peter Crane, Co-Founder and CEO, the company operates "at the nexus of AI and a new era of consumer-driven medicine." He emphasized that current conditions enable the development and launch of medicines in this therapeutic space, with the company's focus now on using its infrastructure to enable both partners and internal programs to develop and de-risk new medicines.
Jamie MacFarlane, General Partner at The Creator Fund (搜索), highlighted a critical issue in AI-driven biology: "Most AI in biology is downstream of weak data. Entelo Bio (搜索) is fixing that at the source. If you believe better inputs drive better outcomes, this is one of the most important companies being built in biology today."
Scientific Foundation and Leadership
Entelo Bio (搜索) was built upon pioneering multi-omics and computational biology research conducted at the Botnar Institute for Musculoskeletal Sciences (搜索) at the University of Oxford. The leadership team includes Dr Peter Crane, who previously worked at Synthace and Infinitopes, and Prof Adam Cribbs, who serves as Musculoskeletal Biological coordinator for the Human Cell Atlas and Group leader at the University of Oxford. The team also includes colleagues from leading data-driven AIxBio companies and global clinical and therapeutic leaders specializing in movement disorder biology.
Investment Perspective
Zoe Peden, Partner at Ananda Impact Ventures (搜索), positioned the investment within broader industry trends: "The rapid diffusion of AI tools and growing societal and economic interest in transforming healthspan are ushering in a new golden era of biology. Entelo Bio (搜索) has built the hard-to-replicate, scalable foundational infrastructure to move these diseases from chance to engineering."
The Creator Fund (搜索)'s early investment in the company reflects confidence in Entelo Bio (搜索)'s foundational approach to addressing data quality issues that have historically limited AI applications in biological research and drug discovery.